{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T16:29:46Z","timestamp":1788798586066,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T00:00:00Z","timestamp":1705363200000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012021","name":"Iran University of Medical Sciences","doi-asserted-by":"publisher","award":["15970"],"award-info":[{"award-number":["15970"]}],"id":[{"id":"10.13039\/100012021","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/j.ctarc.2024.100791","type":"journal-article","created":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T03:51:55Z","timestamp":1705463515000},"page":"100791","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Finding the PSA-based screening stopping age using prostate cancer risk"],"prefix":"10.1016","volume":"38","author":[{"given":"Azin","family":"Nahvijou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Hadian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6336-5363","authenticated-orcid":false,"given":"Naser","family":"Mohamadkhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ctarc.2024.100791_bib0001","first-page":"7","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"10.1016\/j.ctarc.2024.100791_bib0002","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.prnil.2016.07.001","article-title":"Incidence and mortality of prostate cancer and their relationship with the Human Development Index worldwide","volume":"4","author":"Hassanipour-Azgomi","year":"2016","journal-title":"Prostate Int."},{"issue":"3","key":"10.1016\/j.ctarc.2024.100791_bib0003","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"2","key":"10.1016\/j.ctarc.2024.100791_bib0004","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.prnil.2017.11.003","article-title":"The incidence of prostate cancer in Iran: a systematic review and meta-analysis","volume":"6","author":"Hassanipour","year":"2018","journal-title":"Prostate Int."},{"issue":"4","key":"10.1016\/j.ctarc.2024.100791_bib0005","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22041551","article-title":"Treating prostate cancer by antibody-drug conjugates","volume":"22","author":"Rosellini","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.ctarc.2024.100791_bib0006","doi-asserted-by":"crossref","DOI":"10.3390\/cells9092051","article-title":"Is there a role for immunotherapy in prostate cancer?","volume":"9","author":"Rizzo","year":"2020","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.ctarc.2024.100791_bib0007","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13030546","article-title":"Bone targeting agents in patients with metastatic prostate cancer: state of the art","volume":"13","author":"Mollica","year":"2021","journal-title":"Cancers. (Basel)"},{"issue":"11","key":"10.1016\/j.ctarc.2024.100791_bib0008","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.289.11.1414","article-title":"Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence?","volume":"289","author":"Sirovich","year":"2003","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ctarc.2024.100791_bib0009","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1586\/erp.13.26","article-title":"A literature review of cost-effectiveness analyses of prostate-specific antigen test in prostate cancer screening","volume":"13","author":"Garg","year":"2013","journal-title":"Expert. Rev. Pharmacoecon. Outcomes. Res."},{"issue":"18","key":"10.1016\/j.ctarc.2024.100791_bib0010","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1001\/jama.2018.3710","article-title":"Screening for prostate cancer: US preventive services task force recommendation statement","volume":"319","author":"Grossman","year":"2018","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.ctarc.2024.100791_bib0011","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1016\/j.juro.2009.07.093","article-title":"Prostate specific antigen best practice statement: 2009 update","volume":"182","author":"Greene","year":"2009","journal-title":"J. Urol."},{"issue":"10","key":"10.1016\/j.ctarc.2024.100791_bib0012","doi-asserted-by":"crossref","first-page":"761","DOI":"10.7326\/0003-4819-158-10-201305210-00633","article-title":"Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians","volume":"158","author":"Qaseem","year":"2013","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.ctarc.2024.100791_bib0013","doi-asserted-by":"crossref","first-page":"46","DOI":"10.21037\/tau.2017.12.39","article-title":"Stopping screening, when and how?","volume":"7","author":"Hugosson","year":"2018","journal-title":"Transl. Androl. Urol."},{"key":"10.1016\/j.ctarc.2024.100791_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcpo.2023.100443","article-title":"Optimal age to stop prostate cancer screening and early detection","author":"Mohamadkhani","year":"2023","journal-title":"J. Cancer Policy."},{"issue":"4","key":"10.1016\/j.ctarc.2024.100791_bib0015","first-page":"297","article-title":"Cancer screening in the United States, 2018: a review of current American Cancer Society guidelines and current issues in cancer screening","volume":"68","author":"Smith","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"2","key":"10.1016\/j.ctarc.2024.100791_bib0016","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.juro.2010.09.101","article-title":"The prostate cancer risk calculator from the Prostate Cancer Prevention Trial underestimates the risk of high grade cancer in contemporary referral patients","volume":"185","author":"Ngo","year":"2011","journal-title":"J. Urol."},{"issue":"11","key":"10.1016\/j.ctarc.2024.100791_bib0017","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1002\/ijc.33045","article-title":"Personalized strategies in population screening for prostate cancer","volume":"147","author":"Remmers","year":"2020","journal-title":"Int. J. Cancer"},{"issue":"5","key":"10.1016\/j.ctarc.2024.100791_bib0018","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1097\/JU.0000000000000346","article-title":"Personalized risks of over diagnosis for screen detected prostate cancer incorporating patient comorbidities: estimation and communication","volume":"202","author":"Gulati","year":"2019","journal-title":"J. Urol."},{"key":"10.1016\/j.ctarc.2024.100791_bib0019","series-title":"Markov Desicion Process in Practice","first-page":"189","article-title":"Markov Decision Processes for Screening and Treatment of Chronic Diseases","author":"Steimle","year":"2017"},{"issue":"9","key":"10.1016\/j.ctarc.2024.100791_bib0020","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1002\/cncr.20586","article-title":"Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis","volume":"101","author":"Bastian","year":"2004","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ctarc.2024.100791_bib0021","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.urology.2005.03.002","article-title":"Scharfstein DO. Utility of saturation biopsy to predict insignificant cancer at radical prostatectomy","volume":"66","author":"Epstein","year":"2005","journal-title":"Urology."},{"issue":"5","key":"10.1016\/j.ctarc.2024.100791_bib0022","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1097\/01.ju.0000177465.11299.02","article-title":"The independent impact of extended pattern biopsy on prostate cancer stage migration","volume":"174","author":"Master","year":"2005","journal-title":"J. Urol."},{"issue":"4","key":"10.1016\/j.ctarc.2024.100791_bib0023","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1287\/msom.1120.0388","article-title":"Optimization of prostate biopsy referral decisions","volume":"14","author":"Zhang","year":"2012","journal-title":"Manuf. Serv. Oper. Manage."},{"issue":"5","key":"10.1016\/j.ctarc.2024.100791_bib0024","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s11606-016-3629-y","article-title":"An individualized approach to cancer screening decisions in older adults: a multilevel framework","volume":"31","author":"Breslau","year":"2016","journal-title":"J. Gen. Intern. Med."},{"issue":"3","key":"10.1016\/j.ctarc.2024.100791_bib0025","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/jgs.12123","article-title":"Targeting of mammography screening according to life expectancy in women aged 75 and older","volume":"61","author":"Schonberg","year":"2013","journal-title":"J. Am. Geriatr. Soc."},{"issue":"3","key":"10.1016\/j.ctarc.2024.100791_bib0026","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.pec.2008.11.015","article-title":"How does communication heal? Pathways linking clinician-patient communication to health outcomes","volume":"74","author":"Street","year":"2009","journal-title":"Patient. Educ. Couns."},{"issue":"2","key":"10.1016\/j.ctarc.2024.100791_bib0027","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s11606-012-2227-x","article-title":"Individualizing cancer screening in older adults: a narrative review and framework for future research","volume":"28","author":"Eckstrom","year":"2013","journal-title":"J. Gen. Intern. Med."},{"issue":"21","key":"10.1016\/j.ctarc.2024.100791_bib0028","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1001\/jama.285.21.2750","article-title":"Cancer screening in elderly patients: a framework for individualized decision making","volume":"285","author":"Walter","year":"2001","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ctarc.2024.100791_bib0029","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1046\/j.1369-6513.2001.00143.x","article-title":"Increasing informed uptake and non-uptake of screening: evidence from a systematic review","volume":"4","author":"Jepson","year":"2001","journal-title":"Health Expect."},{"issue":"10","key":"10.1016\/j.ctarc.2024.100791_bib0030","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1093\/jnci\/djab072","article-title":"The impact of intensifying prostate cancer screening in black men: a model-based analysis","volume":"113","author":"Nyame","year":"2021","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.ctarc.2024.100791_bib0031","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1093\/jnci\/dju366","article-title":"Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data","volume":"107","author":"Heijnsdijk","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"issue":"20","key":"10.1016\/j.ctarc.2024.100791_bib0032","doi-asserted-by":"crossref","first-page":"7742","DOI":"10.1002\/cam4.3395","article-title":"Assessment of harms, benefits, and cost-effectiveness of prostate cancer screening: a micro-simulation study of 230 scenarios","volume":"9","author":"Getaneh","year":"2020","journal-title":"Cancer Med."},{"key":"10.1016\/j.ctarc.2024.100791_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcpo.2023.100443","article-title":"Optimal age to stop prostate cancer screening and early detection","author":"Mohamadkhani","year":"2023","journal-title":"Journal of Cancer Policy"},{"key":"10.1016\/j.ctarc.2024.100791_bib0034","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1146\/annurev-med-050710-134421","article-title":"Screening for prostate cancer: early detection or overdetection?","volume":"63","author":"Vickers","year":"2012","journal-title":"Annu. Rev. Med."},{"issue":"10","key":"10.1016\/j.ctarc.2024.100791_bib0035","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1200\/JCO.2010.31.2330","article-title":"Impact of comorbidity on survival among men with localized prostate cancer","volume":"29","author":"Albertsen","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.ctarc.2024.100791_bib0036","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s11606-011-1869-4","article-title":"Comorbidities, treatment and ensuing survival in men with prostate cancer","volume":"27","author":"Chamie","year":"2012","journal-title":"J. Gen. Intern. Med."},{"issue":"10","key":"10.1016\/j.ctarc.2024.100791_bib0037","doi-asserted-by":"crossref","first-page":"667","DOI":"10.7326\/0003-4819-159-10-201311190-00005","article-title":"Comorbidity-adjusted life expectancy: a new tool to inform recommendations for optimal screening strategies","volume":"159","author":"Cho","year":"2013","journal-title":"Ann. Intern. Med."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294224000030?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294224000030?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:34:02Z","timestamp":1762842842000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294224000030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":37,"alternative-id":["S2468294224000030"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2024.100791","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Finding the PSA-based screening stopping age using prostate cancer risk","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2024.100791","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100791"}}